- Motley Fool•15 hours ago
How Biogen and Gilead Sciences stack up in a battle of big biotech stocks.
- Motley Fool•17 hours ago
Shares of these three industry leaders are too cheap to pass up.
- Investopedia•20 hours ago
Merck revised its 2016 earnings after recording a $2.9 billion impairment charges for its Hep C drug.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||70.33 x 100|
|Ask||70.50 x 2000|
|Day's Range||69.80 - 70.54|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||7.09|
|Dividend & Yield||2.08 (2.97%)|
|1y Target Est||N/A|